BioMap and Fudan University Unveil EnTao-GPM: World’s First Germline Pathogenic Mutation DNA Foundation Model

Jul 30, 2025 12:01 CST Updated 12:01

BioMap

Developer of Innovative Drug R&D Platform

Recently, the 2025 World Artificial Intelligence Conference and the High-Level Meeting on Global AI Governance (WAIC) grandly opened in Shanghai. The world's first DNA life science vertical large model focused on germline pathogenic mutations — the BioMap Germline Pathogenic Mutation DNA Large Model (referred to as EnTao-GPM, click "Read Original" at the end of the article to view the paper) made a significant appearance at the "AI Evolution·Future Health" industry forum. This milestone achievement was realized through a strategic cooperation between BioMap and the Fudan University Institute of Intelligent Medicine, based on BioMap’s cross-modal life science foundational large model with 210 billion parameters.Combined with Fudan University's high-quality exclusive data，Precisely focusing on the diagnosis of genetic diseases, adding a benchmark case for the vertical application of AI life science large models in the medical industry.

BioMap's Pathogenic Mutation DNA Large Model Debuts at the 2025 World Artificial Intelligence Conference

Fudan University's School of Intelligent Medicine aims to serve China's major national needs and strategic goals, targeting the frontiers of medical science. It is the first institution in China to systematically apply AI to empower and transform disciplines ranging from basic research, new drug development, to clinical applications. It continuously explores the essence and patterns of diseases and pioneers new applications in intelligent diagnosis and treatment methods. BioMap is a global pioneer in large foundational models for life sciences. Its core technology has achieved State-of-the-Art (SOTA) performance across over 200 tasks in drug discovery, biomanufacturing, fundamental research, and healthcare. BioMap provides professional AI agents driven by large foundational models in bioscience to more than 700 global clients, covering dozens of specialized fields.

It is reported that EnTao-GPM is trained based on BioMap's self-developed globally leading DNA all-species large model, xTrimoDNA. Specifically, from the perspective of biomedical research and considering the importance and wide application of genomic data, 26 mammalian genomes were selected for incremental pre-training to construct a foundational DNA model for mammals. Subsequently, the model was fine-tuned using high-quality curated data to enhance its predictive capability for pathogenic mutations, ultimately resulting in the EnTao-GPM life science vertical large model, which predicts the probability of germline pathogenic mutations at genetic mutation sites.

The technical breakthroughs and innovations of this model are reflected in the following aspects:Capable of predicting the pathogenicity of both SNV and Indel type mutations, quantifying mutation pathogenicity into precise pathogenic probability values; designed an efficient inference architecture that supports batch computation for practical application scenarios, achieving low-cost and rapid identification of tens of thousands of mutations at the whole-genome scale to meet clinical rapid application needs.

Dean of Fudan University's Intelligent Medical College, Liu Lei, Delivers Keynote Speech at the 2025 WAIC Event

Liu Lei, Dean of the Intelligent Medical College of Fudan University, stated:"Germinal pathogenic mutations affect over 1 billion people globally (including patients and carriers), causing 150 million families to suffer from diseases such as rare disorders and cancer susceptibility syndromes, resulting in over $100 billion in economic losses annually. Within the 3 billion base pairs of the human genome, only 75,000 pathogenic loci have been identified so far, leaving numerous unknown variants yet to be explored. Precise screening and diagnosis are the core pathways to solving these challenges. Today, Fudan University and BioMap take a historic step forward by combining the dual strengths of BioMap's foundational life science large model and Fudan University’s vast and high-quality germinal pathogenic mutation data. They launched the EnTao-GPM Empowered Healthcare System, breaking the medical resource constraints in genetic disease diagnosis, shortening the diagnostic time for rare disease patients, providing early warnings to high-risk cancer families, and injecting new momentum into global healthcare systems."

At the 2025 WAIC venue, BioMap's Vice President of R&D, Zhang Xiaoming, launched the decoding of the EnTao-GPM large model.

BioMap's Vice President of R&D, Zhang Xiaoming, stated:"The foundational large model of life sciences is the core technology of BioMap. The EnTao-GPM large model, implemented at the Intelligent Medical College of Fudan University this time, represents another successful case of BioMap's xTrimoDNA being applied in vertical medical industry applications. We sincerely thank the leaders and teachers of Fudan University for their high recognition of BioMap’s technical capabilities. Driven by the dual engines of massive research data and specialized life sciences data, AI will undoubtedly continue to bring transformative changes to all fields of medicine. We look forward to deepening our cooperation with Fudan University, promoting more innovative applications based on the foundational large model of life sciences, contributing more AI solutions to the entire industry, advancing precision medicine to new heights, and benefiting patients worldwide."

EnTao-GPM Large Model Marks Another Vertical Breakthrough in Artificial Intelligence and Life Sciences, Continuously Opening New Chapters in Precision Medicine. In the future, BioMap hopes to collaborate with more research institutions and industry partners, relying on leading core technologies of foundational large models in life sciences, to explore cutting-edge applications in drug discovery, biomanufacturing, and healthcare. This will drive more AI-driven intelligent, commercial, and systematic solutions, empowering the advancement of human health to new levels.

If you are interested in cooperation, please feel free to contact: info@biomap.com.

BioMap is a global pioneer in foundational large models for life sciences. Its 210 billion-parameter biolinguistic large model decodes the underlying principles of genomes, proteins, cells, and biological systems, serving as a "biological simulator" that significantly reduces reliance on traditional experimental models, empowering research and development. Currently, BioMap has achieved State-of-the-Art (SOTA) performance across over 200 tasks in drug discovery, biomanufacturing, fundamental research, and healthcare. It provides large model-driven professional AI agents to more than 700 global customers across dozens of specialized fields, integrating data, models, and experimental capabilities to deliver cutting-edge applications such as advanced drug discovery, improved bio-reaction efficiency, biological data interpretation, and knowledge acquisition.

The Institute of Intelligent Medicine at Fudan University, presided over by President Jin Li, an academician, was officially approved for establishment on June 30, 2022. With the goal of serving China's major needs and strategies, it aims at the forefront of medical disciplines to promote the interdisciplinary integration of medicine with humanities, science, engineering, and law. Based on modern medical and natural science theories, it integrates technologies such as big data, cloud computing, and artificial intelligence to uncover the essence and patterns of diseases, exploring intelligent diagnostic and treatment methods and their clinical applications. The Institute of Intelligent Medicine brings together Fudan University’s top disciplines, focusing on the cross-border integration of biomedicine and information technology, balancing scientific innovation and technical services. It enhances data integration and transformation capabilities, advances big-data-driven knowledge discovery and translational applications, leads the development of new medical fields, and elevates the academic level and capacity of medical sciences. Additionally, it cultivates globally-minded, innovative, practically-skilled, and humanistic leaders in both medical and engineering fields, as well as top-tier medical innovators, contributing to the construction of a world-class university with Chinese characteristics.